1. Bacich DJ, Pinto JT, Tong WP, Heston WD (2001) Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome, 12(2):117-123. [DOI:10.1007/s003350010240] [PMID]

2. El Fakiri M, Geis NM, Ayada N, Eder M, Eder AC (2021) PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives. Cancers, 13(16): 3967. [DOI:10.3390/cancers13163967] [PMID] []

3. Ahn T, Roberts MJ, Abduljabar A, Joshi A, Perera M, Rhee H, Wood S, Vela I (2019) A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC) Mol Imaging Biol, 21(5): 799-807. [DOI:10.1007/s11307-018-01307-0] [PMID]

4. Tolkach Y, Gevensleben H, Bundschuh R, Koyun A, Huber D, Kehrer C, Hecking T, Keyver-Paik MD, et al. (2018) Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. Breast Cancer Res Treat, 169(3): 447-455. [DOI:10.1007/s10549-018-4717-y] [PMID]

5. Heitkötter B, Steinestel K, Trautmann M, Grünewald I, Barth P, Gevensleben H, Bögemann M, et al. (2018) Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. Oncotarget, 9(11): 9867-9874. [DOI:10.18632/oncotarget.23984] [PMID] []

6. Samplaski MK, Heston W, Elson P, Magi-Galluzzi C, Hansel DE (2011) Folate hydrolase (prostate-specific membrane [corrected] antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Mod Pathol, 24(11): 1521-9. [DOI:10.1038/modpathol.2011.112] [PMID]

7. Schmidt LH, Heitkötter B, Schulze AB, Schliemann C, Steinestel K, Trautmann M, Marra A, et al. (2017) Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer. PloS one, 12(10): e0186280. [DOI:10.1371/journal.pone.0186280] [PMID] []

8. Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Mühlmann G, Ofner D, Zelger B, Ensinger C, Yang XJ, et al. (2009) Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Human Pathology, 40(12): 1754-1761. [DOI:10.1016/j.humpath.2009.06.003] [PMID]

9. Carlucci G, Ippisch R, Slavik R, Mishoe A, Blecha J, Zhu S (2021) 68Ga-PSMA-11 NDA Approval: A novel and successful academic partnership. J Nucl Med, 62(2):149-155. [DOI:10.2967/jnumed.120.260455] [PMID] []

10. Rathke H, Flechsig P, Mier W, Bronzel M, Mavriopoulou E, Hohenfellner M, Giesel FL, et al. (2019) Dosimetry Estimate and Initial Clinical Experience with 90Y-PSMA-617. J Nucl Med, 60(6): 806-811. [DOI:10.2967/jnumed.118.218917] [PMID]

11. Sun M, Niaz MO, Nelson A, Skafida M, Niaz MJ (2020) Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus, 12(6): e8921. [DOI:10.7759/cureus.8921] [PMID] []

12. Garnuszek P, Karczmarczyk U, Maurin M, Sikora A, Zaborniak J, Pijarowska-Kruszyna J, Jaroń A, et al. (2021) PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties. Int J Mol Sci, 22(5): 2731. https://doi.org/10.3390/ijms22052731 [DOI:10.37247/PAMOL2ED.2.2021.23] [PMID] []

13. Novartis receives FDA Breakthrough Therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). Published online June 16, 2021. Accessed June 16, 2021. https://bit.ly/3gwu4BO.

14. Benešová M, Bauder-Wüst U, Schäfer M, Klika KD, Mier W, Haberkorn U, Kopka K, Eder M (2016) Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. J Med Chem, 59(5): 1761-1775. [DOI:10.1021/acs.jmedchem.5b01210] [PMID]

15. Sharifi M, Yousefnia H, Bahrami-Samani A, Jalilian AR, Zolghadri S, Vaez-Tehrani M, Maus S (2017) Optimized Production Assessment, Compartmental Modeling and Dosimetric Evaluation of 177Lu- PSMA-617 for Clinical Trials. Int J Nucl Med Res, 4(2): 19-29. [DOI:10.15379/2408-9788.2017.04.02.01]

16. Xiaoping Xu, Jianping Zhang, Silong Hu, Simin He, Xiao Bao, Guang Ma, Jianmin Luo, Cheng J, Zhang Y (2017) 99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen. Nucl Med Biol, 48: 69-75. [DOI:10.1016/j.nucmedbio.2017.01.010] [PMID]

17. Zhang J, Zhang J, Xu X, Lu L, Hu S, Liu C, Cheng J, Song S, Zhang Y, Shi LQ (2020) Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer. Sci Rep,10(1): 4179. [DOI:10.1038/s41598-020-61129-5] [PMID] []

18. Maecke H (2005) Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology. Ernst Schering Res Found Workshop, 49: 43-72. [DOI:10.1007/3-540-26809-X_3] [PMID]

19. Edelman MJ, Clamon G, Kahn D, Magram M, Lister-James J, Line BR (2009) Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog. J Thorac Oncol, 4: 1550-1554. [DOI:10.1097/JTO.0b013e3181bf1070] [PMID]

20. Miao Y, Owen NK, Fisher DR, Hoffman TJ, Quinn TP (2005) Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med, 46(1): 121-9.

21. Karamivand M, Mohammadpour-Ghazi F, Zolghadri S, Kalantari B, Alirezapour B, Yousefnia H (2021) Characterization of 188W / 188Re generator and quality control of its eluate. JonSat, 42(4): 120-126.

22. Yousefnia H, Zolghadri S, Jalilian AR (2015) Absorbed dose assessment of 177Lu-zoledronate and 177Lu-EDTMP for human based on biodistribution data in rats. J Med Phys, 40(2): 102-108. [DOI:10.4103/0971-6203.158694] [PMID] []

23. Zolghadri S, Yousefnia H, Jalilian AR, Fazaeli Y (2015) Production, quality control, biodistribution assessment and preliminary dose evaluation of [177Lu]-tetra phenyl porphyrin complex as a possible therapeutic agent. Braz J Pharm Sci, 51(2): 339-348. [DOI:10.1590/S1984-82502015000200011]

24. Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med, 46: 1023-1027.

25. Sharifi M, Jalilian AR, Yousefnia H, Alirezapour B, Bahrami-Samani A, Zolghadri S (2018) Production, quality control, biodistribution and imaging studies of 177Lu-PSMA-617 in breast adenocarcinoma model. Radiochim Acta, 106(6): 507-513. [DOI:10.1515/ract-2017-2874]

26. Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J (2017) Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci, 64(1): 52-60. [DOI:10.1002/jmrs.227] [PMID] []

27. Lepareur N, Lacœuille F, Bouvry C, Hindré F, Garcion E, Chérel M, Noiret N, Garin E, Knapp FFR Jr (2019) Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives. Front Med (Lausanne), 6: 132. [DOI:10.3389/fmed.2019.00132] [PMID] []

28. Kalidindi TM, Lee SG, Jou K, Chakraborty G, Skafida M, Tagawa ST, Bander NH, Schoder H, Bodei L, Pandit-Taskar N, Lewis JS, Larson SM, Osborne JR, Pillarsetty NVK (2021) A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. Eur J Nucl Med Mol Imaging, 48(8): 2642-2651. [DOI:10.1007/s00259-020-05150-w] [PMID] []

29. Sharifi M, Yousefnia H, Zolghadri S, Bahrami-Samani A, Naderi M , Jalilian AR, Geramifar P, Beiki D (2016) Preparation and biodistribution assessment of 68Ga-DKFZ-PSMA-617 for PET prostate cancer imaging. Nucl Sci Tech, 27(6):1-9. [DOI:10.1007/s41365-016-0134-2]

30. Yousefnia H, Zolghadri S, Shanehsazzadeh S (2015) Estimated human absorbed dose of 177Lu-BPAMD based on mice data: Comparison with 177Lu-EDTMP. Appl Radiat Isot, 104: 128-135. [DOI:10.1016/j.apradiso.2015.06.033] [PMID]

31. Kurth J, Krause BJ, Hakenberg O, Schwarzenboeck S, Heuschkel M (2020) [90Y]Y-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer - Post-therapeutic kidney and bone marrow dosimetry for individualized therapy. J Nucl Med, 61(1): 190.

32. Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, Suman S, Basu S, Das T, Banerjee S (2021) Examining Absorbed Doses of Indigenously Developed 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy. Cancer Biother Radiopharm, 36(3): 292-304. [DOI:10.1089/cbr.2020.3640] [PMID]

33. Rosar F, Schön N, Bohnenberger H, Bartholomä M, Stemler T, Maus S, Khreish F, et al. (2021) Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy. EJNMMI Phys, 8(1): 40. [DOI:10.1186/s40658-021-00385-4] [PMID] []